HomeBUSINESS
BUSINESS

Ayumi Looks to Haul in Over 10 Billion Yen from 3 RA Biosimilars: President
(Dec.1.2017)

Ayumi President Hikaru Ouchi
Rheumatoid arthritis (RA) specialty firm Ayumi Pharmaceutical launched a biosimilar version of Remicade (infliximab) on November 29, making a foray into the Japanese biosimilar market. With two more RA biosimilars also in the wings, the company is shooting for over 10 billion yen in combined sales of these three products, President Hikaru Ouchi tells Jiho ...
(LOG IN FOR FULL STORY)